{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T17:21:09Z","timestamp":1793467269321,"version":"4.5.0"},"reference-count":22,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Psoriasis is a chronic, inflammatory skin disease in which the interleukin (IL)\u201023\/IL\u201017 axis plays a central role. Bimekizumab is a novel antibody that targets both IL\u201017A and IL\u201017F. This retrospective study aimed to assess the long\u2010term effectiveness and safety of 52\u2010week treatment with bimekizumab, and to identify predictive factors for short\u2010 (16\u2009weeks) and long\u2010term (52\u2009weeks) responders (i.e., achievers of a Psoriasis Area and Severity Index (PASI) score of 100) to bimekizumab in Japanese patients with psoriasis. The study was conducted on 56 Japanese patients (aged \u2265\u200915\u2009years) with moderate\u2010to\u2010severe psoriasis treated with bimekizumab from May 2022 to March 2024. The therapeutic effectiveness was evaluated by the transition of PASI scores during treatment. Baseline characteristics and clinical and laboratory indexes were compared between responders and poor responders. Treatment\u2010emergent adverse events (TEAEs) were recorded to assess the safety of the treatment. At week 52, the achievement of PASI 100, static Physician's Global Assessment 0\/1, and the Dermatology Life Quality Index 0\/1 were 72.4%, 94.7%, and 93.3%, respectively. Short\u2010term responders showed lower baseline values of neutrophil\u2010to\u2010lymphocyte ratio, monocyte\u2010to\u2010lymphocyte ratio (MLR), and systemic inflammatory response index compared to poor responders. Long\u2010term responders showed younger age and lower MLR compared to poor responders. TEAEs were mild or moderate, without serious adverse events. Long\u2010term treatment with bimekizumab is effective and safe for psoriasis patients. Lower MLR and younger age might predict long\u2010term response to treatment with bimekizumab, aiding in personalized treatment strategies.<\/jats:p>","DOI":"10.1111\/1346-8138.17532","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T13:03:34Z","timestamp":1730811814000},"page":"317-328","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Effectiveness of long\u2010term bimekizumab treatment and predictive factors for responders in moderate\u2010to\u2010severe psoriasis: A 52\u2010week real\u2010world study"],"prefix":"10.1111","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4183-9596","authenticated-orcid":false,"given":"Teppei","family":"Hagino","sequence":"first","affiliation":[{"name":"Department of Dermatology Nippon Medical School Chiba Hokusoh Hospital  Inzai Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1095-0355","authenticated-orcid":false,"given":"Hidehisa","family":"Saeki","sequence":"additional","affiliation":[{"name":"Department of Dermatology Nippon Medical School  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eita","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Fujimoto Dermatology Clinic  Funabashi Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4389-2312","authenticated-orcid":false,"given":"Naoko","family":"Kanda","sequence":"additional","affiliation":[{"name":"Department of Dermatology Nippon Medical School Chiba Hokusoh Hospital  Inzai Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12946"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12051934"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12030974"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16866"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00125-2"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00126-4"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102383"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00883-y"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17186"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12083046"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1323174"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/5701949"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23179553"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13230"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102388"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.05.001"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1772454"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad035"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.3109\/15569527.2013.834498"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13061"},{"key":"e_1_2_8_22_1","first-page":"5160","article-title":"Age\u2010associated alteration in Th17 cell response is related to endothelial cell senescence and atherosclerotic cerebral infarction","volume":"9","author":"Li Q","year":"2017","journal-title":"Am J Transl Res"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/819149"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.17532","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T17:28:48Z","timestamp":1747675728000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.17532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1111\/1346-8138.17532"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.17532","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,5]]},"assertion":[{"value":"2024-07-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}